{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:54:35Z","timestamp":1783464875374,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.clml.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:33:14Z","timestamp":1630168394000},"page":"98-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-636X","authenticated-orcid":false,"given":"Mohammad","family":"Ammad Ud Din","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarthkumar","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ather","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hania","family":"Liaqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeqa","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3434-6136","authenticated-orcid":false,"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.08.006_bib0001","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"Goede","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.006_bib0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.006_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2021.08.006_bib0004","first-page":"S44","article-title":"Atrial fibrillation and bleeding in patients with chronic lymphocytic leukemia treated with ibrutinib in the veterans health administration","volume":"37","author":"Rasmussen","year":"2020","journal-title":"Fed Pract"},{"key":"10.1016\/j.clml.2021.08.006_bib0005","first-page":"18","article-title":"Three Fold Risk of Atrial Fibrillation in Ibrutinib Treated CLL Patients without Increased Risk of Stroke: A SEER-Medicare Database Analysis","volume":"136","author":"Diamond","year":"2020","journal-title":"In Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2017-08-764712","article-title":"How I treat CLL patients with ibrutinib","volume":"131","author":"Jennifer","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0007","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1182\/blood-2018-99-112679","article-title":"Patterns of ibrutinib use, discontinuation, and hospitalization among patients with chronic lymphocytic leukemia (CLL) in a US healthcare claims database","volume":"132","author":"To","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0008","unstructured":"HCUP Databases, Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, Rockville, MD, August 2018, www. hcupus.ahrq. gov\/nisoverview.jsp, Accessed: November 2020."},{"key":"10.1016\/j.clml.2021.08.006_bib0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjcard.2020.12.024","article-title":"Impact of arrhythmias on hospitalizations in patients with cardiac amyloidosis","volume":"143","author":"Thakkar","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clml.2021.08.006_bib0010","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.006_bib0011","series-title":"Presented at: American Society of Hematology (ASH) 57th Annual Meeting; December 5-8","article-title":"Characterization of atrial fibrillation and bleeding risk factors in patients with chronic lymphocytic leukemia (CLL): a population- based retrospective cohort study of administrative medical claims data in the United States (US)","author":"Barrientos","year":"2015"},{"key":"10.1016\/j.clml.2021.08.006_bib0012","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2021.08.006_bib0013","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0014","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.08.006_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.08.006_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.08.006_bib0017","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.08.006_bib0018","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0019","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.08.006_bib0020","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O'Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.08.006_bib0021","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.08.006_bib0024","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.006_bib0025","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.08.006_bib0026","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2018-99-114899","article-title":"Scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia and its validation in a cohort of ibrutinib-treated patients","volume":"132","author":"Visentin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0027","first-page":"3301","article-title":"The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): an international study","volume":"126","author":"Thompson","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open heart"},{"key":"10.1016\/j.clml.2021.08.006_bib0022","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1002\/cam4.2134","article-title":"Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors","volume":"8","author":"Georgantopoulos","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2021.08.006_bib0023","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ahj.2004.11.015","article-title":"Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"DiMarco","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.clml.2021.08.006_bib0029","first-page":"1491","article-title":"Ibrutinib-Associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC: Clin Electrophysiol"},{"key":"10.1016\/j.clml.2021.08.006_bib0030","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1080\/10428194.2017.1315115","article-title":"Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib","volume":"58","author":"Chai","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.08.006_bib0031","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood-2018-11-846808","article-title":"How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia","volume":"133","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.08.006_bib0032","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"supple 1","key":"10.1016\/j.clml.2021.08.006_bib0033","first-page":"4326","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in hematologic malignancies","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021003645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:50Z","timestamp":1761871190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021003645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2152265021003645"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Atrial Fibrillation on hospitalization Outcomes for Patients With Chronic Lymphocytic Leukemia Using the National Inpatient Sample Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}